Steven Dodson, PhD
Senior Director, Pharmacology
Steve Dodson comes to CODA with deep expertise in the discovery and early development of small molecule therapeutics targeting ion channels. Steve is former Senior Director, Drug Discovery and Development at Second Genome, Inc. where he was responsible for the advancement of the SGM-1019 program through Phase I for the treatment of Nonalcoholic Steatohepatitis. Prior to that, he was Director of Drug Discovery and Development at NeuroTherapeutics Pharma, Inc. where he was responsible for a discovery program targeting a unique ligand gated ion channel with a novel mechanism of action for the treatment of epilepsy and neuropathic pain; and Director, Molecular Pharmacology at Renovis, Inc. where he directed a molecular pharmacology group responsible for drug target assay development and small molecule compound evaluation to support multiple drug discovery programs in pain, CNS indications and inflammation. He is also a cofounder of Myotherix, Inc. a company focused on discovering and developing novel therapeutics for the treatment of degenerative muscle disorders through the modulation of calcium handling.
Steve received his B.S. in Genetics from U.C. Berkeley and his Ph.D. in Biological Sciences from Stanford University.